The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses
Open accessAbstract
Molecular characterization of the severe acute respiratory syndrome coronavirus has revealed genetic diversity among isolates. The spike (S) glycoprotein, the major target for vaccine and immune therapy, shows up to 17 substitutions in its 1,255-aa sequence; however, the biologic significance of these changes is unknown. Here, the functional effects of S mutations have been determined by analyzing their affinity for a viral receptor, human angiotensin-converting enzyme 2 (hACE-2), and their sensitivity to Ab neutralization with viral pseudotypes. Although minor differences among eight strains transmitted during human outbreaks in early 2003 were found, substantial functional changes were detected in S derived from a case in late 2003 from Guangdong province [S(GD03T0013)] and from two palm civets, S(SZ3) and S(SZ16). S(GD03T0013) depended less on the hACE-2 receptor and was markedly resistant to Ab inhibition. Unexpectedly, Abs that neutralized most human S glycoproteins enhanced entry mediated by the civet virus S glycoproteins. The mechanism of enhancement involved the interaction of Abs with conformational epitopes in the hACE-2-binding domain. Finally, improved immunogens and mAbs that minimize this complication have been defined. These data show that the entry of severe acute respiratory syndrome coronaviruses can be enhanced by Abs, and they underscore the need to address the evolving diversity of this newly emerged virus for vaccines and immune therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M.-H., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,474
Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,406
The Genome Sequence of the SARS-Associated Coronavirus
Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A., Butterfield, Y. S. N., Khattra, J., Asano, J. K., Barber, S. A., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,026
Pathogenesis of dengue: challenges to molecular biology
Halstead, S. (1988) · Science · doi:10.1126/science.239.4839.476 · Cited by 1,614
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499
Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L. M., Guan, Y., Rozanov, M., Spaan, W. J. M., & Gorbalenya, A. E. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00865-9 · Cited by 1,198
Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China
The Chinese SARS Molecular Epidemiology Consortium (2004) · Science · doi:10.1126/science.1092002 · Cited by 775
Episomal Vectors Rapidly and Stably Produce High-Titer Recombinant Retrovirus
Kinsella, T. M., & Nolan, G. P. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.12-1405 · Cited by 734
Cited by
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
Lau, S. K. P., Woo, P. C. Y., Li, K. S. M., Huang, Y., Tsoi, H.-W., Wong, B. H. L., Wong, S. S. Y., Leung, S.-Y., Chan, K.-H., & Yuen, K.-Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506735102 · Cited by 1,544
Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus
Weiss, S. R., & Navas-Martin, S. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.4.635-664.2005 · Cited by 1,256
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-07 · Cited by 1,192
Xia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G. F., Tan, W., Wu, G., Xu, M., Lou, Z., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30831-8 · Cited by 1,144
Chan, J. F. W., Lau, S. K. P., To, K. K. W., Cheng, V. C. C., Woo, P. C. Y., & Yuen, K.-Y. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 881
Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.008 · Cited by 748
Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026
ter Meulen, J., van den Brink, E. N., Poon, L. L. M., Marissen, W. E., Leung, C. S. W., Cox, F., Cheung, C. Y., Bakker, A. Q., Bogaards, J. A., van Deventer, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030237 · Cited by 612
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Poland, G. A., Ovsyannikova, I. G., & Kennedy, R. B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32137-1 · Cited by 572
The potential danger of suboptimal antibody responses in COVID-19
Iwasaki, A., & Yang, Y. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0321-6 · Cited by 509
Immunopathogenesis of coronavirus infections: implications for SARS
Dandekar, A. A., & Perlman, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1732 · Cited by 499
T Cell Responses to Whole SARS Coronavirus in Humans
Li, C. K.-F., Wu, H., Yan, H., Ma, S., Wang, L., Zhang, M., Tang, X., Temperton, N. J., Weiss, R. A., Brenchley, J. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5490 · Cited by 497
Ortiz-Prado, E., Simbaña-Rivera, K., Gómez- Barreno, L., Rubio-Neira, M., Guaman, L. P., Kyriakidis, N. C., Muslin, C., Jaramillo, A. M. G., Barba-Ostria, C., Cevallos-Robalino, D., et al. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115094 · Cited by 458
Is COVID-19 receiving ADE from other coronaviruses?
Tetro, J. A. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.02.006 · Cited by 434
The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development
Dutta, N. K., Mazumdar, K., & Gordy, J. T. (2020) · Journal of Virology · doi:10.1128/jvi.00647-20 · Cited by 410
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
Lei, C., Qian, K., Li, T., Zhang, S., Fu, W., Ding, M., & Hu, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16048-4 · Cited by 392
Sims, A. C., Baric, R. S., Yount, B., Burkett, S. E., Collins, P. L., & Pickles, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15511-15524.2005 · Cited by 349
Bai, Z., Cao, Y., Liu, W., & Li, J. (2021) · Viruses · doi:10.3390/v13061115 · Cited by 348
Proinflammatory IgG Fc structures in patients with severe COVID-19
Chakraborty, S., Gonzalez, J., Edwards, K., Mallajosyula, V., Buzzanco, A. S., Sherwood, R., Buffone, C., Kathale, N., Providenza, S., Xie, M. M., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00828-7 · Cited by 326
Jaume, M., Yip, M. S., Cheung, C. Y., Leung, H. L., Li, P. H., Kien, F., Dutry, I., Callendret, B., Escriou, N., Altmeyer, R., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00671-11 · Cited by 314
Wang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., Zhu, H., Liu, J., Xu, Y., Xie, J., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00006 · Cited by 304
Evaluation of candidate vaccine approaches for MERS-CoV
Wang, L., Shi, W., Joyce, M. G., Modjarrad, K., Zhang, Y., Leung, K., Lees, C. R., Zhou, T., Yassine, H. M., Kanekiyo, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8712 · Cited by 299
Self-citationPotent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
Zhu, Z., Chakraborti, S., He, Y., Roberts, A., Sheahan, T., Xiao, X., Hensley, L. E., Prabakaran, P., Rockx, B., Sidorov, I. A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701000104 · Cited by 287
Self-citationMolecular epidemiology, evolution and phylogeny of SARS coronavirus
Luk, H. K. H., Li, X., Fung, J., Lau, S. K. P., & Woo, P. C. Y. (2019) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2019.03.001 · Cited by 280
Li, W., Wong, S.-K., Li, F., Kuhn, J. H., Huang, I.-C., Choe, H., & Farzan, M. (2006) · Journal of Virology · doi:10.1128/jvi.80.9.4211-4219.2006 · Cited by 276
Deming, D., Sheahan, T., Heise, M., Yount, B., Davis, N., Sims, A., Suthar, M., Harkema, J., Whitmore, A., Pickles, R., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 275
Lau, S. K. P., Li, K. S. M., Huang, Y., Shek, C.-T., Tse, H., Wang, M., Choi, G. K. Y., Xu, H., Lam, C. S. F., Guo, R., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02219-09 · Cited by 273
Bats, Civets and the Emergence of SARS
Wang, L. F., & Eaton, B. T. (2007) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-70962-6_13 · Cited by 271
Yount, B., Roberts, R. S., Sims, A. C., Deming, D., Frieman, M. B., Sparks, J., Denison, M. R., Davis, N., & Baric, R. S. (2005) · Journal of Virology · doi:10.1128/jvi.79.23.14909-14922.2005 · Cited by 253
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000583 · Cited by 181
Eliciting B cell immunity against infectious diseases using nanovaccines
Singh, A. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00790-3 · Cited by 169
Wang, L., Shi, W., Chappell, J. D., Joyce, M. G., Zhang, Y., Kanekiyo, M., Becker, M. M., van Doremalen, N., Fischer, R., Wang, N., et al. (2018) · Journal of Virology · doi:10.1128/jvi.02002-17 · Cited by 169
Self-citationQuinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M. S., Luo, G., Li, W., Zhong, G., et al. (2020) · doi:10.1101/2020.04.10.036418 · Cited by 140
“, 2016), and SARS-CoV-1 ADE has been observed by several groups in cell culture studies (Jaume et al., 2011; Liu et al., 2019; Wan et al., 2020; Wang et al., 2014; Yang et al., 2005; Yip et al., 2014).”
BackgroundHe, Y., Li, J., Heck, S., Lustigman, S., & Jiang, S. (2006) · Journal of Virology · doi:10.1128/jvi.00083-06 · Cited by 135
“Recently, it was reported that a DNA vaccine that expresses the full-length S protein (Urbani) induced antibodies that neutralized the 2002 to 2003 human SARS-CoV isolates but were not effective in neutralizing the 2003 to 2004 human SARS-CoV isolates and even enhanced infection mediated by the S proteins of palm cive…”
BackgroundInfluentialRockx, B., Corti, D., Donaldson, E., Sheahan, T., Stadler, K., Lanzavecchia, A., & Baric, R. (2008) · Journal of Virology · doi:10.1128/jvi.02377-07 · Cited by 134
Self-citationCoughlin, M., Lou, G., Martinez, O., Masterman, S. K., Olsen, O. A., Moksa, A. A., Farzan, M., Babcook, J. S., & Prabhakar, B. S. (2007) · Virology · doi:10.1016/j.virol.2006.09.029 · Cited by 70
Metadata
- Authors
- Yang, Z.-Y., Werner, H. C., Kong, W.-P., Leung, K., Traggiai, E., Lanzavecchia, A., & Nabel, G. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-01-10
- Volume
- 102
- Issue
- 3
- Pages
- 797-801
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1969773218
- Cited by
- 253
- References
- 25
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.